Rational mutagenesis to support structure-based drug design: MAPKAP kinase 2 as a case study

BACKGROUND: Structure-based drug design (SBDD) can provide valuable guidance to drug discovery programs. Robust construct design and expression, protein purification and characterization, protein crystallization, and high-resolution diffraction are all needed for rapid, iterative inhibitor design. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Argiriadi, Maria A, Sousa, Silvino, Banach, David, Marcotte, Douglas, Xiang, Tao, Tomlinson, Medha J, Demers, Megan, Harris, Christopher, Kwak, Silvia, Hardman, Jennifer, Pietras, Margaret, Quinn, Lisa, DiMauro, Jennifer, Ni, Baofu, Mankovich, John, Borhani, David W, Talanian, Robert V, Sadhukhan, Ramkrishna
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2678131/
https://www.ncbi.nlm.nih.gov/pubmed/19296855
http://dx.doi.org/10.1186/1472-6807-9-16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2678131/
https://www.ncbi.nlm.nih.gov/pubmed/19296855
http://dx.doi.org/10.1186/1472-6807-9-16

Ejemplares similares